Dayvigo Cost in Illinois 2026: Lemborexant Price, Insurance & Savings

Dayvigo (lemborexant) is a brand-name, FDA-approved prescription medication for insomnia disorder in adults, approved in December 2019 under NDA 211775. It belongs to a drug class called dual orexin receptor antagonists (DORAs), which work by blocking wake-promoting orexin signaling rather than broadly sedating the central nervous system, the mechanism used by older sleep drugs like benzodiazepines and zolpidem. Lemborexant is a federally controlled Schedule IV substance. There is no FDA-approved generic tablet version as of this writing.

The useful question for an Illinois patient is not "what does Dayvigo cost" but "which cost lever applies to me." A single national or state-average price figure cannot describe what any individual will pay, because the actual out-of-pocket cost depends on which insurer and pharmacy benefit manager processes the claim, whether prior authorization has been approved, which pharmacy fills it, and whether a manufacturer savings program applies that month. Those variables change often enough that a number printed in an article can be stale within weeks. What is stable is the regulatory and clinical framework around the drug; what is volatile is the price and coverage rule sitting on top of it. This article separates the two, and the checklist below is built specifically to help you tell which category a given fact belongs to before you rely on it.

What is actually established

• Dayvigo (lemborexant) is FDA-approved for insomnia disorder in adults, at doses of 5 mg or 10 mg taken at bedtime with at least 7 hours planned before waking. The label warns of complex sleep behaviors (including sleepwalking and sleep-driving) and next-morning impairment, particularly at the 10 mg dose, and lemborexant is contraindicated in narcolepsy. Coadministration with moderate or strong CYP3A4 inhibitors is not recommended because it meaningfully raises lemborexant exposure. These are FDA-label facts and are not expected to change with the calendar year, though the label itself should be checked for the current version.
• Lemborexant is a Schedule IV controlled substance, which affects how it can be prescribed, refilled, and transmitted electronically.
• Federal law under Section 503A of the Food, Drug and Cosmetic Act allows state-licensed compounding pharmacies to prepare patient-specific, non-mass-produced medications, including lemborexant, for an individual patient with a valid prescription. Lemborexant is not on FDA's list of bulk drug substances authorized for large-scale 503B outsourcing-facility production, so compounding is limited to individual-patient 503A preparation, not bulk manufacturing.
• Compounded lemborexant is not FDA-approved and has not undergone bioequivalence testing against brand Dayvigo. Differences in dissolution, absorption, or potency between a compounded capsule and the FDA-approved tablet are possible and have not been formally studied; a prescriber should be part of any decision to switch between the two.
• Medicare Part D plans are generally required to offer some coverage for Schedule IV drugs that are otherwise formulary-eligible, but the specific tier, copay, and prior authorization rules are set by each individual plan, not by CMS directly.

What is plausible but not something this article can verify

Randomized controlled trials supporting the original FDA approval compared lemborexant to placebo and, in at least one trial, to an active comparator in adults with insomnia disorder, and reported improvements in measures such as sleep onset latency and wake after sleep onset over multi-week and longer follow-up periods. The general direction of that evidence, that lemborexant outperforms placebo on these endpoints in the approval trials, is consistent with how FDA came to approve the drug. However, specific numeric results (exact minutes of improvement, exact responder percentages, exact p-values) that circulate in secondary write-ups should be checked against the FDA label and the original trial publications rather than taken from a summary article, including this one. This draft does not carry those numbers because the underlying citations could not be confirmed as pointing to the correct papers.

Guideline bodies including the American Academy of Sleep Medicine have addressed pharmacologic treatment of chronic insomnia in adults, and DORAs including lemborexant and suvorexant are generally discussed as options rather than first-line therapy in the guideline literature available on this topic. The exact wording, grade of recommendation, and publication year of the current guideline should be confirmed directly from AASM before being quoted in patient materials, since guideline text changes between revisions and a paraphrase risks misstating the strength of the recommendation.

What is not established, or is specific to a payer and therefore cannot be stated as a fixed fact

Illinois Medicaid's prior authorization criteria for lemborexant, the exact step-therapy requirements, the specific PA form number, and the re-authorization interval are set by the Illinois Department of Healthcare and Family Services and can change with quarterly preferred drug list updates. This article cannot state a specific current requirement without a live citation to the Illinois HFS preferred drug list, and readers should confirm current criteria directly with HFS or their managed care plan rather than relying on a static description.

Any single dollar figure for Dayvigo's list price, a "statewide average" cash-pay price in Illinois, specific pharmacy-by-pharmacy price comparisons, commercial PBM tier placements, copay amounts, or the terms of a manufacturer savings card (including maximum annual savings) are the kind of numbers that shift throughout the year and differ by plan. No verified, dated source for Illinois-specific 2026 figures was available for this draft, so none are presented as fact here. If a number appears anywhere else describing Illinois lemborexant pricing without a date and a named source, treat it as unverified.

Illinois Medicaid coverage: the general shape, with limits stated plainly

Illinois Medicaid, like most state Medicaid programs, typically requires prior authorization for brand-name, non-first-line insomnia medications, and commonly expects documentation of a trial of a generic first-line agent (such as zolpidem or eszopiclone) before approving a DORA. This is a reasonable expectation based on how state Medicaid formularies are generally structured, but the specific Illinois criteria, form, and approval window described in older versions of this page could not be confirmed against a current HFS source and have been removed rather than repeated as fact. Anyone pursuing Illinois Medicaid coverage for Dayvigo should ask their prescriber's office to check current PA criteria directly with HFS or the relevant managed care organization (for example, Meridian, Molina, Aetna Better Health of Illinois, or Blue Cross Community Health Plans) before assuming a specific process.

Is compounded lemborexant legal in Illinois?

Yes, in the limited sense that federal law permits 503A compounding pharmacies, when licensed and inspected under state pharmacy law, to prepare individual-patient lemborexant prescriptions. Illinois licenses pharmacies through the Illinois Department of Financial and Professional Regulation. A 503A pharmacy generally cannot ship a compounded controlled substance across state lines to fill an out-of-state order; the patient and the prescribing relationship typically need a connection to the state where the pharmacy is located.

This legality is narrower than it may sound. It does not mean compounded lemborexant is FDA-approved, tested for bioequivalence, or automatically appropriate as a substitute for brand Dayvigo. It also does not mean every compounding pharmacy in Illinois offers lemborexant, or that pricing is uniform; that has to be confirmed pharmacy by pharmacy.

Telehealth prescribing in Illinois

Telehealth prescribing of Schedule IV controlled substances, including lemborexant, is generally permitted in many states when a prescriber holds an active controlled-substance license in that state and completes a clinical evaluation adequate to support the prescription. Federal rules governing telemedicine prescribing of controlled substances without a prior in-person visit have been the subject of ongoing regulatory activity and temporary extensions at the federal level, and the current status should be checked against the DEA and FDA's public statements as of the date you are reading this, since these rules have changed more than once. A responsible telehealth evaluation for insomnia should cover sleep history, daytime functional impairment, substance use history, and screening for obstructive sleep apnea, since untreated OSA is a clinically relevant consideration before starting a sedative-hypnotic, even where it is not listed as a formal contraindication on the label.

Comparing cost levers without inventing numbers

Zolpidem and eszopiclone are available generically and are typically far less expensive than any brand DORA; this is why they are commonly used as Medicaid and commercial step-therapy requirements before a DORA is approved. Suvorexant, another DORA, has a generic version and is likely to be less expensive than brand Dayvigo, though a specific price comparison for Illinois pharmacies in 2026 was not available to verify for this draft. Trazodone, used off-label for insomnia, and low-dose doxepin are lower-cost options some Illinois Medicaid prescribers use before a DORA prior authorization is submitted.

If a prescriber and patient have a clinical reason to prefer lemborexant specifically, such as its longer half-life or the dosing flexibility between 5 mg and 10 mg, that reasoning should be documented in any prior authorization request, since payers generally want a stated clinical rationale for choosing a non-preferred agent over a cheaper alternative.

Verification checklist: stable facts vs. facts you must re-check

Use this before quoting a price, coverage rule, or legal claim about Dayvigo or compounded lemborexant in Illinois.

Stable, federal or clinical facts (safe to rely on without a fresh check, but confirm the label version):

• FDA-approved indication: insomnia disorder in adults; approved December 2019, NDA 211775
• Available doses: 5 mg and 10 mg tablets
• DEA schedule: Schedule IV controlled substance
• Contraindication: narcolepsy
• Label warning: complex sleep behaviors and next-morning impairment, especially at 10 mg
• Drug interaction principle: moderate/strong CYP3A4 inhibitors increase lemborexant exposure and are not recommended concomitantly
• Legal framework for compounding: FD&C Act Section 503A permits patient-specific compounding by licensed pharmacies; lemborexant is not authorized for 503B bulk/outsourcing production
• No FDA-approved generic lemborexant tablet exists as of this writing

Date-sensitive facts you must re-verify before acting on them (do not treat any number here as current unless you confirm it yourself):

• Dayvigo's list price or WAC this month
• Any "average" cash-pay price at Illinois pharmacies
• Whether your specific commercial plan or PBM places Dayvigo on a given formulary tier
• Whether prior authorization is required by your plan, and its exact criteria
• Illinois Medicaid's current preferred drug list status and PA requirements for lemborexant, via Illinois HFS
• Terms, eligibility, and maximum savings of any manufacturer copay card
• Whether a specific Illinois compounding pharmacy currently compounds lemborexant, and its price
• Current federal telemedicine-prescribing rules for controlled substances without a prior in-person visit
• Your specific Medicare Part D plan's tier and copay for Dayvigo

How to re-verify each date-sensitive item:

1. Call the pharmacy directly and ask for the current cash price and whether a discount card is already applied.
2. Log into your insurer's member portal and search the formulary by drug name, not drug class.
3. Ask your prescriber's office to submit a prior authorization request and to state the specific denial reason if one occurs, since that reason often names the missing documentation.
4. Check the manufacturer's official program page directly rather than relying on a third-party summary of its terms.
5. For Illinois Medicaid, ask the HFS pharmacy benefits line or your managed care plan for the current preferred drug list status, since it updates quarterly.

When to seek care instead of troubleshooting cost

Cost and coverage questions should not delay care if you are experiencing new or worsening excessive daytime sleepiness, signs of sleep apnea (loud snoring, witnessed pauses in breathing, morning headaches), sleepwalking or other complex behaviors while on lemborexant, or impairment the next morning that affects driving. Those are clinical safety issues to raise with a prescriber promptly, separate from any pricing decision.

Frequently asked, evidence-limited questions

Does Illinois Medicaid cover Dayvigo? Illinois Medicaid, like most Medicaid programs, generally requires prior authorization for non-first-line insomnia medications such as Dayvigo. The specific current criteria and form should be confirmed with Illinois HFS or your managed care plan, since this article could not verify a static version of that process as current.

Is compounded lemborexant legal in Illinois? Yes, an Illinois-licensed 503A compounding pharmacy may legally compound lemborexant for an individual patient under a valid, patient-specific prescription. It is not FDA-approved, has not been bioequivalence-tested against brand Dayvigo, and cannot generally be shipped across state lines.

Is there a generic version of Dayvigo? No FDA-approved generic lemborexant tablet was available as of this writing. Compounded lemborexant from a 503A pharmacy is not the same thing as an FDA-approved generic.

Can I get Dayvigo prescribed through telehealth in Illinois? Telehealth prescribing of Schedule IV medications is generally permitted when the prescriber is properly licensed and completes an adequate clinical evaluation, but the federal rules governing prescribing without a prior in-person visit have shifted over time and should be checked against current DEA and FDA guidance before assuming a specific process applies.

References

This article summarizes general regulatory and clinical information and flags where Illinois-specific pricing and coverage claims from an earlier draft could not be verified. It is not a substitute for checking current formulary, pharmacy, and state Medicaid sources, and it is not individualized medical or dosing advice. It is pending qualified clinical and editorial review before publication.